Abstract 4142906: Efficacy and Safety of Aficamten in Patients Guideline-Eligible for Septal Reduction Therapy in the FOREST-HCM Trial
Year: 2024
Type: conference-abstract
Source: Circulation
Authors: Ahmad Masri, Lubna Choudhury, Pablo Garcia-Pavia, Theodore Abraham, Roberto Barriales-Villa, ozlem bilen, Perry Elliott, Albert Hagege, Sherif Nagueh, Srihari Naidu, Michael Nassif, Iacopo Olivotto, Artur Oreziak, Anjali Owens, Omar Wever-Pinzon, Albree Tower Rader, Stephen Heitner, Stuart Kupfer, Fady Malik, Chiara Melloni, Lixin Meng, Jenny Wei, Sara Saberi
Institutions: Oregon Health & Science University, Northwestern University, Spanish National Centre for Cardiovascular Research, Centro de Investigación en Red en Enfermedades Cardiovasculares, Hospital Universitario Puerta de Hierro Majadahonda, University of California, San Francisco, Complexo Hospitalario Universitario A Coruña, Emory University, University College London, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Houston Methodist, Westchester Medical Center, New York Medical College, Saint Luke's Hospital, Meyer Children's Hospital, Istituti di Ricovero e Cura a Carattere Scientifico, Institute of Cardiology, University of Pennsylvania, University of Utah, Massachusetts General Hospital, Cytokinetics (United States), University of Michigan
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4404359987